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Letters to the EditorSilibinin in hepatitis C related liver transplantationReply to Beinhardt et al.:
We congratulate Beinhardt et al. for their interesting paper
about successful prevention of hepatitis C virus (HCV) reinfec-
tion by short-term administration of high-dose silibinin infu-
sions before and after OLT [1]. Preventing HCV reinfection
has an enormous impact on the long term outcome of liver
transplantation. Since interferon alpha based treatment regi-
mens are not tolerated early after OLT and also in most
instances in the pre-transplant setting, silibinin mono therapy
seems to be a promising treatment option – supported by its
reasonable safety proﬁle, as documented by its use in ama-
nita-induced acute liver failure.
Success or failure of preventing re-infection with a short term
silibinin mono therapy seems to depend mainly on the level of
hepatitis C viremia at the time of OLT. The breakdown of hepatitis
C viremia, usually seen during the anhepatic phase, works syner-
gistically with the direct antiviral effect of silibinin infusion to
support the prevention of re-infection.
As an additional mode of action, a direct inhibitory effect of
silymarin components towards the viral entry into hepatocytes
has been proposed in vitro [2].
In both cases, in ours [3] and the one reported by Beinhardt
et al. [1], HCV RNA levels were low at the time of OLT and partic-
ularly after the anhepatic phase (range of 102 IU/ml). The
approach reported here includes a silibinin treatment before
OLT, hereby signiﬁcantly lowering viremia in order to provide
beneﬁcial conditions for the successful prevention of re-infection.
This might signiﬁcantly enlarge the pool of patients beneﬁting
from post-OLT silibinin infusions. However, since the exact tim-
ing of the transplantation is usually not feasible, a standardiza-
tion of the reported procedure seems to be difﬁcult and is
probably only possible in the setting of living donor liver trans-
plantation (LDLT).592 Journal of Hepatology 20Up to now little is known about the safety of high dose sil-
ibinin infusions in the setting of end stage chronic liver disease.
In our hands patients with advanced cirrhosis showed a
marked elevation of bilirubin (mainly indirect) in response to
silibinin infusions – an observation that was not seen in
patients with mild or moderate ﬁbrosis. The clinical signiﬁ-
cance of this bilirubin elevation remains unclear. At the same
time this ﬁnding is obviously affecting MELD-score depending
organ allocation.
Clearly the potential of silibinin infusions in the peri-trans-
plant period in HCV infected patients needs further evaluation.
Studies should address several open questions as the optimal
duration of treatment after OLT, the safety and effectiveness of
silibinin infusions before OLT, and the potentially enhancing
effect of adding ribavirin to silibinin infusions.
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To the Editor:
Several elegant studies, summarised in their review by the
Coagulation in Liver Disease Study Group, have helped in
changing the paradigm of bleeding related to liver disease, from
abnormal coagulation proﬁle to haemostatic alterations second-
ary to portal hypertension, endogenous heparinoids, sepsis, and
renal failure [1]. However, one of the key omissions in this
respect is the role of anemia in worsening the haemorrhagic
tendency of liver dysfunction. Anemia is common in individuals
with chronic liver disease and is likely to be of multifactorial
etiology including folate deﬁciency, hypersplenism, hemodilu-
tion, haemolysis, bone marrow suppression due to viruses or
ethanol, renal insufﬁciency, and, most importantly, variceal
bleeding. How anemia would worsen the bleeding tendency in
these patients has not been directly studied but several factors
are responsible.
Firstly, anemia worsens the hyperdynamic circulation, the key
pathogenetic feature of portal hypertension [2]. This is possibly
due to the reduction in blood viscosity but some evidence for
the role of the vasodilator nitric oxide (NO) has also been sug-
gested [3]. As demonstrated in experimental animals, NO may
also play a central role in the systemic and splanchnic vasodila-
tion associated with portal hypertension with increased vascular
responses to speciﬁc inhibitors of NO biosynthesis [2]. Secondly,
there is evidence that red blood cells not only have passive, rhe-
ological effects on blood coagulation but also actively stimulate
thrombin generation [4]. The best example of the haemostatic
role of red cells is represented by the increased thrombotic ten-
dency of polycythemia and erythropoiesis-stimulating agents.
Interestingly, a small prospective study of 42 patients with
chronic anemia (unrelated to liver disease) shown an unex-
plained improvement in the activated partial thromboplastin
time but not in the prothrombin time measured before and after
the transfusion of packed red cells [5].
By far, the most likely explanation for the bleeding tendency
with anemia is the effect of red cells on platelet function. Red cells
release adenosine diphosphate which promotes platelet aggrega-
tion and also stimulates platelet synthesis of thromboxane A2, a
key platelet activator during vessel injury. Haemoglobin could
also play an important role because of its high afﬁnity for NO.
The reduced NO scavenging, caused by the reduced level of hae-
moglobin in anemia, activates guanylyl cyclase and further
impairs platelet aggregation. Moreover, in normal physiological
states, red cells, being the largest cells, tend to occupy the central
part of the vasculature, pushing the platelets nearer to the vessel
wall, where they are poised to respond to injury. In anemic states,
the concentration of platelets in proximity to the endothelium is
reduced thus affecting the haemostatic process. The beneﬁcial
effect of red cells on platelet function was ﬁrst reported by Duke
in 1910 but was conclusively proved by Hellem who examined
anemic patients with bleeding defects showing a decrease in
bleeding time
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